Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Launched the National Policy on Infant and Young Child Feeding

 
Deputy Prime Minister and Health Minister Ghassan Hasbani launched “the national policy on infant and young child feeding” during a press conference at the premises of the Ministry in collaboration with the UNICEF.

“We need fewer drugs when we take good care of our children’s health. If breastfeeding was widely spread we wouldn’t need large quantities of drugs,” said Hasbani
.
He stressed that the Ministry of Public Health was eager to ensure good nutrition and an environment suitable for that. It was also keen to provide the best drugs in terms of quality and price. He also reminded of the amendments introduced to the drugs’ pricing mechanism, which started to be implemented.

Hasbani mentioned that the first practical step of these decisions was implemented by reviewing the prices of the generic drugs that were higher than that of their branded versions.

“The memorandum No. 114 issued on 27 November 2018 included 303 generic drugs of which prices were reduced by 20%, knowing that the reduction reached a maximum of 73%,” Hasbani added.

The ministry will continue to reduce the prices of drugs, as it will reconsider the prices of 1630 drugs within two weeks as said before. The re-pricing of drugs will include 3440 drugs during the first half of 2019.

Talking about infant and young child nutrition in Lebanon, Hasbani mentioned that the rates of exclusive breastfeeding up to six months are very low (14.8%) and breastfeeding infants up to two years of age remains a considerable challenge due to the lack of the necessary support.

 Hasbani noted that the Ministry had taken many steps and initiatives in collaboration with many partners during the last ten years to improve the nutrition of infants and young children, most important of which are the following:
  • The promulgation of law No. 47/2008 that regulates the marketing of the nutritional products for infants
  • The formation of a national committee in 2010 on the nutrition of infants and young children
  • The implementation of Baby-Friendly Hospital Initiative (BFHI) in 16 hospitals.
  • The organization of national campaigns to encourage breastfeeding.
    1
    ...
ATC Name B/G Ingredients Dosage Form Price
A05AA04 OCALIVA B Obeticholic acid - 10mg 10mg Tablet, film coated 224,503,943 L.L
A05AA04 OCALIVA B Obeticholic acid - 5mg 5mg Tablet, film coated 224,503,943 L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 300mg/10ml 300mg/10ml Injectable concentrate for solution L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 300mg/10ml 300mg/10ml Injectable concentrate for solution 547,517,314 L.L
L04AA36 OCREVUS BioTech Ocrelizumab - 920mg/23ml 920mg/23ml Injectable solution 1,095,034,629 L.L
J06BA02 OCTAGAM BioHuman Human normal immunoglobulin G - 50mg/ml 2.5g/50ml Injectable solution 19,540,934 L.L
J06BA02 OCTAGAM BioHuman Human normal immunoglobulin G - 50mg/ml 5g/100ml Injectable solution 37,672,334 L.L
J06BA02 OCTAGAM BioHuman Human normal immunoglobulin G - 50mg/ml 10g/200ml Injectable solution 74,515,099 L.L
J06BA02 OCTAGAM 10% BioHuman Human normal immunoglobulin G - 10% 5g/50ml Injectable solution 37,672,334 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 250IU 250IU Injectable lyophilised powder for solution+diluent 13,247,110 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 500IU 500IU Injectable lyophilised powder for solution+diluent 26,495,478 L.L
B02BD02 OCTANATE BioHuman Coagulation Factor VIII - 1,000IU 1,000IU Injectable lyophilised powder for solution+diluent 46,817,511 L.L
B02BD04 OCTANINE F BioHuman Plasma coagulation factor IX, human - 500IU 500IU Injectable freeze dried powder + diluent 31,425,075 L.L
B02BD01 OCTAPLEX BioHuman Prothrombin complex, human (PPSB) - 500IU 500IU Injectable powder for solution+diluent 35,220,164 L.L
A04AA01 ODNATRON G Ondansetron (HCl dihydrate) - 4mg/2ml 4mg/2ml Injectable solution 880,217 L.L
A04AA01 ODNATRON G Ondansetron (HCl dihydrate) - 8mg/4ml 8mg/4ml Injectable solution 952,784 L.L
G03CA03 OESTRACLIN G Estradiol - 0.6mg/g 0.6mg/g Gel 448,843 L.L
G03CA03 OESTRODOSE B Estradiol (17 bêta estradiol anhydre) - 0.06% 0.06% Gel 642,357 L.L
L01EX09 OFEV B Nintedanib - 150mg 150mg Capsule, soft L.L
L01EX09 OFEV B Nintedanib - 100mg 100mg Capsule, soft 104,970,427 L.L
L01EX09 OFEV B Nintedanib - 150mg 150mg Capsule, soft 209,943,960 L.L
J01MA01 OFLACIN G Ofloxacin - 200mg 200mg Tablet, film-scored 602,041 L.L
J01MA01 OFLOMED G Ofloxacin - 200mg 200mg Tablet, film-scored 601,530 L.L
S02AA16 OFLOMED G Ofloxacin - 3mg/ml 3mg/ml Drops solution 317,403 L.L
S01AE01 OFLOX B Ofloxacin - 3mg/ml 0.3% Drops solution 366,869 L.L
S01AE01 OFLOX B Ofloxacin - 0.3% 0.3% Drops solution 366,869 L.L
L01FD01 OGIVRI BioTech Trastuzumab - 440mg 440mg Injectable lyophilised powder 80,027,615 L.L
N05AH03 OLANZAMED G Olanzapine - 5mg 5mg Tablet 665,522 L.L
N05AH03 OLANZAMED G Olanzapine - 20mg 20mg Tablet 3,941,938 L.L
N05AH03 OLANZAMED G Olanzapine - 10mg 10mg Tablet 902,294 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026